Try a new search

Format these results:

Searched for:

in-biosketch:true

person:mayerm04

Total Results:

150


CXCR4 PET imaging of mantle cell lymphoma using [68Ga]Pentixafor: comparison with [18F]FDG-PET

Mayerhoefer, Marius E; Raderer, Markus; Lamm, Wolfgang; Pichler, Verena; Pfaff, Sarah; Weber, Michael; Kiesewetter, Barbara; Hacker, Markus; Kazianka, Lukas; Staber, Philipp B; Wester, Hans-Juergen; Rohrbeck, Johannes; Simonitsch-Klupp, Ingrid; Haug, Alexander
For PET imaging of mantle cell lymphoma (MCL), [18F]FDG (2-deoxy-2-[18F]fluoro-D-glucose) is the currently recommended radiotracer, although uptake is variable and bone marrow evaluation is limited. In this prospective study, we evaluated the novel CXCR4 (G-protein-coupled C-X-C chemokine receptor type 4) tracer [68Ga]Pentixafor in MCL patients, and compared it to [18F]FDG. Methods: MCL patients underwent [68Ga]Pentixafor-PET/MRI, and, if required for routine purposes, also [18F]FDG-PET/MRI, before treatment. PET was evaluated separately for 23 anatomic regions (12 lymph node stations and 11 organs/tissues), using MRI as the main reference standard. Standardized uptake values (SUVmax and SUVmean) and tumor-to-background ratios (TBRblood and TBRliver) were calculated. General Estimation Equations (GEE) were used to compare [68Ga]Pentixafor-PET and [18F]FDG-PET sensitivities and positive predictive values (PPV). For bone marrow involvement, where biopsy served as the main reference standard, and splenic involvement, receiver operating characteristic curves were used to determine the optimal SUV and TBR cut-off values, and areas under the curve (AUC) were calculated. Results: Twenty-two MCL patients were included. [68Ga]Pentixafor-PET sensitivity (100%) was significantly higher than for [18F]FDG-PET (75.2%) (P<0.001), and PPV was slightly, but not significantly lower (94.0%.vs. 96.5%; P=0.21). SUVs and TBRs were significantly higher for [68Ga]Pentixafor-PET than for [18F]FDG-PET (P<0.001 in all cases); the greatest difference was observed for mean TBRblood, with 4.9 for [68Ga]Pentixafor-PET and 2.0 for [18F]FDG-PET. For bone marrow involvement, [68Ga]Pentixafor-PET SUVmean showed an AUC of 0.92; and for splenic involvement, TBRblood showed an AUC of 0.81. Conclusion: [68Ga]Pentixafor-PET may become an alternative to [18F]FDG-PET in MCL patients, showing clearly higher detection rates and better tumor-to-background contrast.
PMCID:7738870
PMID: 33391493
ISSN: 1838-7640
CID: 5596182

Correction to: Incorporating radiomics into clinical trials: expert consensus endorsed by the European Society of Radiology on considerations for data-driven compared to biologically driven quantitative biomarkers

Fournier, Laure; Costaridou, Lena; Bidaut, Luc; Michoux, Nicolas; Lecouvet, Frederic E; de Geus-Oei, Lioe-Fee; Boellaard, Ronald; Oprea-Lager, Daniela E; Obuchowski, Nancy A; Caroli, Anna; Kunz, Wolfgang G; Oei, Edwin H; O'Connor, James P B; Mayerhoefer, Marius E; Franca, Manuela; Alberich-Bayarri, Angel; Deroose, Christophe M; Loewe, Christian; Manniesing, Rashindra; Caramella, Caroline; Lopci, Egesta; Lassau, Nathalie; Persson, Anders; Achten, Rik; Rosendahl, Karen; Clement, Olivier; Kotter, Elmar; Golay, Xavier; Smits, Marion; Dewey, Marc; Sullivan, Daniel C; van der Lugt, Aad; deSouza, Nandita M; ,
PMID: 33693997
ISSN: 1432-1084
CID: 5596192

Single-Cell RNA Sequencing Reveals Tissue Compartment-Specific Plasticity of Mycosis Fungoides Tumor Cells

Rindler, Katharina; Bauer, Wolfgang M; Jonak, Constanze; Wielscher, Matthias; Shaw, Lisa E; Rojahn, Thomas B; Thaler, Felix M; Porkert, Stefanie; Simonitsch-Klupp, Ingrid; Weninger, Wolfgang; Mayerhoefer, Marius E; Farlik, Matthias; Brunner, Patrick M
Mycosis fungoides (MF) is the most common primary cutaneous T-cell lymphoma. While initially restricted to the skin, malignant cells can appear in blood, bone marrow and secondary lymphoid organs in later disease stages. However, only little is known about phenotypic and functional properties of malignant T cells in relationship to tissue environments over the course of disease progression. We thus profiled the tumor micromilieu in skin, blood and lymph node in a patient with advanced MF using single-cell RNA sequencing combined with V-D-J T-cell receptor sequencing. In skin, we identified clonally expanded T-cells with characteristic features of tissue-resident memory T-cells (TRM, CD69+CD27-NR4A1+RGS1+AHR+
PMCID:8097053
PMID: 33968070
ISSN: 1664-3224
CID: 5596212

Radiomics of high-resolution computed tomography for the differentiation between cholesteatoma and middle ear inflammation: effects of post-reconstruction methods in a dual-center study

Arendt, Christophe T; Leithner, Doris; Mayerhoefer, Marius E; Gibbs, Peter; Czerny, Christian; Arnoldner, Christoph; Burck, Iris; Leinung, Martin; Tanyildizi, Yasemin; Lenga, Lukas; Martin, Simon S; Vogl, Thomas J; Schernthaner, Ruediger E
OBJECTIVES/OBJECTIVE:To evaluate the performance of radiomic features extracted from high-resolution computed tomography (HRCT) for the differentiation between cholesteatoma and middle ear inflammation (MEI), and to investigate the impact of post-reconstruction harmonization and data resampling. METHODS:One hundred patients were included in this retrospective dual-center study: 48 with histology-proven cholesteatoma (center A: 23; center B: 25) and 52 with MEI (A: 27; B: 25). Radiomic features (co-occurrence and run-length matrix, absolute gradient, autoregressive model, Haar wavelet transform) were extracted from manually defined 2D-ROIs. The ten best features for lesion differentiation were selected using probability of error and average correlation coefficients. A multi-layer perceptron feed-forward artificial neural network (MLP-ANN) was used for radiomics-based classification, with histopathology serving as the reference standard (70% of cases for training, 30% for validation). The analysis was performed five times each on (a) unmodified data and on data that were (b) resampled to the same matrix size, and (c) corrected for acquisition protocol differences using ComBat harmonization. RESULTS:Using unmodified data, the MLP-ANN classification yielded an overall median area under the receiver operating characteristic curve (AUC) of 0.78 (0.72-0.84). Using original data from center A and resampled data from center B, an overall median AUC of 0.88 (0.82-0.99) was yielded, while using ComBat harmonized data, an overall median AUC of 0.89 (0.79-0.92) was revealed. CONCLUSION/CONCLUSIONS:Radiomic features extracted from HRCT differentiate between cholesteatoma and MEI. When using multi-centric data obtained with differences in CT acquisition parameters, data resampling and ComBat post-reconstruction harmonization clearly improve radiomics-based lesion classification. KEY POINTS/CONCLUSIONS:• Unenhanced high-resolution CT coupled with radiomics analysis may be useful for the differentiation between cholesteatoma and middle ear inflammation. • Pooling of data extracted from inhomogeneous CT datasets does not appear meaningful without further post-processing. • When using multi-centric CT data obtained with differences in acquisition parameters, post-reconstruction harmonization and data resampling clearly improve radiomics-based soft-tissue differentiation.
PMCID:8128805
PMID: 33277670
ISSN: 1432-1084
CID: 5475812

Multidisciplinary Recommendations Regarding Post-Vaccine Adenopathy and Radiologic Imaging: Radiology Scientific Expert Panel

Becker, Anton S; Perez-Johnston, Rocio; Chikarmane, Sona A; Chen, Melissa M; El Homsi, Maria; Feigin, Kimberly N; Gallagher, Katherine M; Hanna, Ehab Y; Hicks, Marshall; Ilica, Ahmet T; Mayer, Erica L; Shinagare, Atul B; Yeh, Randy; Mayerhoefer, Marius E; Hricak, Hedvig; Vargas, H Alberto
Vaccination-associated adenopathy is a frequent imaging finding after administration of COVID-19 vaccines that may lead to a diagnostic conundrum in patients with manifest or suspected cancer, in whom it may be indistinguishable from malignant nodal involvement. To help the medical community address this concern in the absence of studies and evidence-based guidelines, this special report offers recommendations developed by a multidisciplinary panel of experts from three of the leading tertiary care cancer centers in the United States. According to these recommendations, some routine imaging examinations, such as those for screening, should be scheduled before or at least 6 weeks after the final vaccination dose to allow for any reactive adenopathy to resolve. However, there should be no delay of other clinically indicated imaging (eg, for acute symptoms, short-interval treatment monitoring, urgent treatment planning or complications) due to prior vaccination. The vaccine should be administered on the side contralateral to the primary or suspected cancer, and both doses should be administered in the same arm. Vaccination information-date(s) administered, injection site(s), laterality, and type of vaccine-should be included in every preimaging patient questionnaire, and this information should be made readily available to interpreting radiologists. Clear and effective communication between patients, radiologists, referring physician teams, and the general public should be considered of the highest priority when managing adenopathy in the setting of COVID-19 vaccination.
PMID: 33625298
ISSN: 1527-1315
CID: 5452872

An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases

Husseini, Jad S; Amorim, Bárbara Juarez; Torrado-Carvajal, Angel; Prabhu, Vinay; Groshar, David; Umutlu, Lale; Herrmann, Ken; Cañamaque, Lina García; Garzón, José Ramón García; Palmer, William E; Heidari, Pedram; Shih, Tiffany Ting-Fang; Sosna, Jacob; Matushita, Cristina; Cerci, Juliano; Queiroz, Marcelo; Muglia, Valdair Francisco; Nogueira-Barbosa, Marcello H; Borra, Ronald J H; Kwee, Thomas C; Glaudemans, Andor W J M; Evangelista, Laura; Salvatore, Marco; Cuocolo, Alberto; Soricelli, Andrea; Herold, Christian; Laghi, Andrea; Mayerhoefer, Marius; Mahmood, Umar; Catana, Ciprian; Daldrup-Link, Heike E; Rosen, Bruce; Catalano, Onofrio A
BACKGROUND:MR is an important imaging modality for evaluating musculoskeletal malignancies owing to its high soft tissue contrast and its ability to acquire multiparametric information. PET provides quantitative molecular and physiologic information and is a critical tool in the diagnosis and staging of several malignancies. PET/MR, which can take advantage of its constituent modalities, is uniquely suited for evaluating skeletal metastases. We reviewed the current evidence of PET/MR in assessing for skeletal metastases and provided recommendations for its use. METHODS:We searched for the peer reviewed literature related to the usage of PET/MR in the settings of osseous metastases. In addition, expert opinions, practices, and protocols of major research institutions performing research on PET/MR of skeletal metastases were considered. RESULTS:Peer-reviewed published literature was included. Nuclear medicine and radiology experts, including those from 13 major PET/MR centers, shared the gained expertise on PET/MR use for evaluating skeletal metastases and contributed to a consensus expert opinion statement. [18F]-FDG and non [18F]-FDG PET/MR may provide key advantages over PET/CT in the evaluation for osseous metastases in several primary malignancies. CONCLUSION/CONCLUSIONS:PET/MR should be considered for staging of malignancies where there is a high likelihood of osseous metastatic disease based on the characteristics of the primary malignancy, hight clinical suspicious and in case, where the presence of osseous metastases will have an impact on patient management. Appropriate choice of tumor-specific radiopharmaceuticals, as well as stringent adherence to PET and MR protocols, should be employed.
PMID: 33619599
ISSN: 1619-7089
CID: 4806792

Positive selection as the unifying force for clonal evolution in multiple myeloma [Letter]

Diamond, Benjamin; Yellapantula, Venkata; Rustad, Even H; Maclachlan, Kylee H; Mayerhoefer, Marius; Kaiser, Martin; Morgan, Gareth; Landgren, Ola; Maura, Francesco
PMID: 33483619
ISSN: 1476-5551
CID: 4788272

MRI and PET/MRI in hematologic malignancies

Mayerhoefer, Marius E; Archibald, Stephen J; Messiou, Christina; Staudenherz, Anton; Berzaczy, Dominik; Schöder, Heiko
The role of MRI differs considerably between the three main groups of hematological malignancies: lymphoma, leukemia, and myeloma. In myeloma, whole-body MRI (WB-MRI) is recognized as a highly sensitive test for the assessment of myeloma, and is also endorsed by clinical guidelines, especially for detection and staging. In lymphoma, WB-MRI is presently not recommended, and merely serves as an alternative technique to the current standard imaging test, [18 F]FDG-PET/CT, especially in pediatric patients. Even for lymphomas with variable FDG avidity, such as extranodal mucosa-associated lymphoid tissue lymphoma (MALT), contrast-enhanced computed tomography (CT), but not WB-MRI, is presently recommended, despite the high sensitivity of diffusion-weighted MRI and its ability to capture treatment response that has been reported in the literature. In leukemia, neither MRI nor any other cross-sectional imaging test (including positron emission tomography [PET]) is currently recommended outside of clinical trials. This review article discusses current clinical applications as well as the main research topics for MRI, as well as PET/MRI, in the field of hematological malignancies, with a focus on functional MRI techniques such as diffusion-weighted imaging and dynamic contrast-enhanced MRI, on the one hand, and novel, non-FDG PET imaging probes such as the CXCR4 radiotracer [68 Ga]Ga-Pentixafor and the amino acid radiotracer [11 C]methionine, on the other hand. Level of Evidence: 5 Technical Efficacy Stage: 3 J. Magn. Reson. Imaging 2020;51:1325-1335.
PMCID:7217155
PMID: 31260155
ISSN: 1522-2586
CID: 5597542

Whole-Body [18F]FDG-PET/MRI vs. [18F]FDG-PET/CT in Malignant Melanoma

Berzaczy, Dominik; Fueger, Barbara; Hoeller, Christoph; Haug, Alexander R; Staudenherz, Anton; Berzaczy, Gundula; Weber, Michael; Mayerhoefer, Marius E
PURPOSE:F]FDG PET/x-ray computed tomography (CT) for detection of distant metastatic disease in patients with malignant melanoma. PROCEDURES:F]FDG dual-imaging protocol that included whole-body PET/CT and subsequent whole-body PET/MRI for staging or restaging purposes in a prospective setting. Images from both modalities were analyzed by two rater teams for the presence of metastatic lesions. PET/CT-PET/MRI overall agreement as well as region-based accuracies, sensitivities (Se), and specificities (Sp) were computed. RESULTS:Between July 2014 and December 2018, 22 patients were enrolled. Interrater agreement and overall accuracy (consensus reading) were 78.8 % (95 % CI 71-84.9) and 96.1 % (95 % CI 92.3-98) for PET/MRI and 78 % (70.2-84.3) and 97.4 % (95 % CI 93.7-98.9) for PET/CT, respectively (P = 0.42). PET/MRI reached a region-based Se of 89.1 % (95 % CI 79.4-94.5) and a Sp of 100 %, whereas PET/CT showed a region-based Se of 92.7 % (95 % CI 84-96.9) and a Sp of 100 % for the detection of metastatic disease in malignant melanoma. CONCLUSIONS:F]FDG-PET/CT for lesion detection in patients with malignant melanoma.
PMID: 31363965
ISSN: 1860-2002
CID: 5595952

Introduction to Radiomics

Mayerhoefer, Marius E; Materka, Andrzej; Langs, Georg; Häggström, Ida; Szczypiński, Piotr; Gibbs, Peter; Cook, Gary
Radiomics is a rapidly evolving field of research concerned with the extraction of quantitative metrics-the so-called radiomic features-within medical images. Radiomic features capture tissue and lesion characteristics such as heterogeneity and shape and may, alone or in combination with demographic, histologic, genomic, or proteomic data, be used for clinical problem solving. The goal of this continuing education article is to provide an introduction to the field, covering the basic radiomics workflow: feature calculation and selection, dimensionality reduction, and data processing. Potential clinical applications in nuclear medicine that include PET radiomics-based prediction of treatment response and survival will be discussed. Current limitations of radiomics, such as sensitivity to acquisition parameter variations, and common pitfalls will also be covered.
PMCID:9374044
PMID: 32060219
ISSN: 1535-5667
CID: 5597522